| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 14, 2024 |
| Accession Number: | 0001104659-24-033269 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $15.00 | Buy | Lake Street |
| 11/1/2021 | $15.00 | Outperform | Robert W. Baird |
| 11/1/2021 | Outperform | William Blair | |
| 11/1/2021 | $15.00 | Outperform | Baird |
| 10/22/2021 | $14.00 | Outperform | Cowen & Co. |
RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023. "Our third quarter results were highlighted by continued quarterly improvements in our key profitability metrics and cash burn rate," stated David Coman, Chief Executive Officer of Science 37. "We look forward to a strong finish to the year and positive momentum headed into 2024." Quarterly Financial Highlights Gross bookings were $17.9 million for the quarter ended September 30, 2023, a 50.6%
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023. The Science 37 management team will host a conference call to discuss these results on November 7, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13741458 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the i
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended June 30, 2023. "The actions we have taken over the past nine months are leading to meaningful improvements as evidenced by our sequential quarterly results including growth in gross bookings and gross profit margins along with a reduction in cash burn," stated David Coman, Chief Executive Officer of Science 37. "We look forward to finishing the year strong and continuing to position the company for sustainable financial growth and shareholder value creation." Quarterly Financial
15-12G - Science 37 Holdings, Inc. (0001819113) (Filer)
EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)
EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
3/A - Science 37 Holdings, Inc. (0001819113) (Issuer)
MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company's role in a registrational Phase 3 asthma study, which Science 37 contributed 28% of the total patient enrollment. The FDA evaluated internal processes, technology, data integrity, patien
MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing
MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial
Lake Street initiated coverage of Science 37 with a rating of Buy and set a new price target of $15.00
Robert W. Baird initiated coverage of Science 37 with a rating of Outperform and set a new price target of $15.00
William Blair initiated coverage of Science 37 Hldgs with a rating of Outperform
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company's Chief Commercial Officer, Van Horn's appointment follows his pivotal role in driving operational excellence and shaping the company's strategic direction to better prioritize client success – initiatives credited with driving growth for the company. Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing
RESEARCH TRIANGLE PARK, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company's direct-to-patient recruitment and retention efforts. Prior to IQVIA, Erica spent 11 years with Acurian through the acquisition by PPD where she was Head of Enrollment Opera
RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in India, Pakistan, and Slovakia. This key appointment reflects Science 37's commitment to quality as it expands operations globally. Irena brings nearly two decades of experience in clinical research quality assurance, having held senior leadership positions at KCR and Novella Clinical (now IQVIA